Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Canadian Sec - Delayed Quote CAD

Onco-Innova (ONCO.CN)

1.4500
+0.0300
+(2.11%)
At close: 3:59:30 PM EDT

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
NameTitlePayExercisedYear Born
Mr. Thomas O'Shaughnessy Chief Executive Officer -- -- 1977
Mr. Nico Mah CFO & Corporate Secretary -- -- 1996
Dr. Fadia Saad M.B.A., Ph.D. Consultant -- -- 1964
Dr. Frederick West Technology Transfer Advisor -- -- --

Onco-Innova

1309 - 7th Street SW
Calgary, AB T2R 1A5
Canada
https://oncoinnovations.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1

Description

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.

Corporate Governance

Onco-Innova’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers